Client News

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Hamburg, Germany; Paris, France, 08 March 2018 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research … Continue reading “Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform”

By Optimum

Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec

HASSELT, Belgium, and CHEPSTOW, UK, 7th March 2018 Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced the appointment of William Jenkins, M.D., … Continue reading “Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec”

By Optimum

STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor

STORM Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics’ successful Series A Financing Extension announced in January … Continue reading “STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor”

By Optimum

DelSiTech Ltd and C-Tri Co. Ltd Sign a Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology

DelSiTech Ltd, a Finnish drug delivery technology and development company, and C-Tri Co. Ltd, a Korean KOSDAQ listed biopharmaceutical company, have signed a Partnership and Collaboration Agreement to develop long-acting … Continue reading “DelSiTech Ltd and C-Tri Co. Ltd Sign a Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology”

By Optimum

RYSE announces partnership with DigitalHealth.London to invest in early stage digital health businesses

Applications open today for RYSE Early Stage Opportunity Fund London, 27 November 2017 – RYSE Asset Management LLP (“RYSE”), the investment and advisory boutique, has partnered with DigitalHealth.London in a new venture which … Continue reading “RYSE announces partnership with DigitalHealth.London to invest in early stage digital health businesses”

By Optimum

Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 … Continue reading “Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH